Proteins and Peptides
31 March 2014
Halozyme Announces that Consistent 1 Trial Of Hylenex® Recombinant Met Primary Endpoint31 March 2014
rEVO Biologics Inc. Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn® in Early-Onset Preeclampsia28 March 2014
Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome27 March 2014
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate27 March 2014
Merck Announces Initiation of Phase III Fertility Study with Pergoveris in Poor Ovarian Response Patients26 March 2014
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)25 March 2014
Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-50124 March 2014
Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin DeficiencyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports